Biotechnology

Kendall Square 1987
Biotech

Developers are scrambling for the next Kendall Square. Where will it be?

By Tim Logan

Fatty Liver
Biotech

With NASH results, Intercept Pharma will seek approval for first-ever treatment for fatty liver condition

By Adam Feuerstein

Jim Wilson
Biotech

Once a ‘refugee,’ a gene therapy pioneer finds a renewed calling as the field advances

By Damian Garde

Cambridge flood
Business

Hurricanes, droughts, and wildfires: How biopharma is girding for climate change

By Kate Sheridan

The Readout LOUD

LISTEN: The AI hype machine, ketamine’s future, and the rocky path ahead for NASH

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Something ventured illo
Biotech

Something Ventured: Finch Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?

By Kate Sheridan

John V. Oyler, CEO of BeiGene
Biotech

For a Chinese cancer drug developer, Bristol-Celgene deal is poised to have big ripple effects

By Rebecca Robbins

Fatty Liver
Adam's Take

What’s next in NASH? 6 things to know following the failure of Gilead’s lead drug for fatty liver disease

By Adam Feuerstein

David A. Sinclair
Biotech

Longevity scientists launch academy to raise profile of life-extending research

By Robert Weisman — Boston Globe

Taking notes at conference
First Opinion

The J.P. Morgan Healthcare Conference has grown. How can we make it work for everyone?

By Dennis Purcell

Newborns
First Opinion

Embryo editing for higher IQ is a fantasy. Embryo profiling for it is almost here

By Erik Parens, Paul Appelbaum, and Wendy Chung

Millipore CEO Udit Batra
Biotech

MilliporeSigma CEO Udit Batra on gene editing, business in China, and the company’s funky logo

By Kate Sheridan

Hepatitis Drugs
Biotech

A fatty liver drug from Gilead Sciences posts negative results in late-stage clinical trial

By Adam Feuerstein

Cholesterol blood test
Biotech

Regeneron and Sanofi cut Praluent price 60 percent, as low-selling cholesterol drugs become a drug pricing laboratory

By Matthew Herper

Joel S. Marcus
Business

Real estate tycoon’s investment trust sues his son — and he responds in kind

By Jonathan Saltzman — Boston Globe

Jennifer Doudna
Biotech

University of California to be granted long-sought CRISPR patent, possibly reviving dispute with the Broad Institute

By Sharon Begley

Alexandria Ocasio-Cortez
Biotech

A tweet from Alexandria Ocasio-Cortez prompts a deeper debate over how drugs are made

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Bellus Health, OncoSec Medical

By Adam Feuerstein

Play
The Readout LOUD

Listen: A bad day for bold biotech, campaign 2020, and where do drugs come from?

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Sangamo zinc fingers illo
Biotech

First attempt at genome editing in U.S. patients produces disappointing — and sobering — results

By Adam Feuerstein

Breast Cancer Cell
Biotech

New York biotech debuts, targeting dormant metastatic cancer cells

By Sharon Begley

Chemotherapy infusion
Biotech

Macrogenics offers major surprise with positive breast cancer data, as shares double

By Matthew Herper

IV hand black background
Biotech

With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease

By Adam Feuerstein

Biotech

After a stormy winter, biotech’s IPO hopes hang on a billion-dollar Alzheimer’s company

By Damian Garde

John and Megan Crowley
Biotech

Amicus presents positive data on Pompe drug, but could wait years for approval

By Matthew Herper

Hepatitis Drugs
Adam's Take

Gilead’s new CEO hasn’t shown up for work yet, leaving the biotech rudderless, investors anxious

By Adam Feuerstein

Play
Biotech

Watch: What is a biosimilar, exactly?

By Damian Garde

Josh Hillman
Health

‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress

By Andrew Joseph

Play
The Readout LOUD

Listen: Another Alzheimer’s setback, crypto for biotech, and a blessing of unicorns

By Damian Garde and Rebecca Robbins

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy